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Expression of Cholera Toxin B–Proinsulin Fusion Protein in Lettuce and Tobacco
Chloroplasts – Oral Administration Protects Against Development of Insulitis in
Non-Obese Diabetic Mice
Abstract
Lettuce and tobacco chloroplast transgenic lines expressing the cholera toxin B subunit–human
proinsulin (CTB-Pins) fusion protein were generated. CTB-Pins accumulated up to ~16% of total soluble
protein (TSP) in tobacco and up to ~2.5% of TSP in lettuce. Eight milligrams of powdered tobacco leaf
material expressing CTB-Pins or, as negative controls, CTB–green fluorescent protein (CTB-GFP) or
interferon–GFP (IFN-GFP), or untransformed leaf, were administered orally, each week for 7 weeks, to
5-week-old female non-obese diabetic (NOD) mice. The pancreas of CTB-Pins-treated mice showed
decreased infiltration of cells characteristic of lymphocytes (insulitis); insulin-producing β-cells in the
pancreatic islets of CTB-Pins-treated mice were significantly preserved, with lower blood or urine glucose
levels, by contrast with the few β-cells remaining in the pancreatic islets of the negative controls.
Increased expression of immunosuppressive cytokines, such as interleukin-4 and interleukin-10 (IL-4 and
IL-10), was observed in the pancreas of CTB-Pins-treated NOD mice. Serum levels of immunoglobulin G1
(IgG1), but not IgG2a, were elevated in CTB-Pins-treated mice. Taken together, T-helper 2 (Th2)
lymphocyte-mediated oral tolerance is a likely mechanism for the prevention of pancreatic insulitis and
the preservation of insulin-producing β-cells. This is the first report of expression of a therapeutic protein
in transgenic chloroplasts of an edible crop. Transplastomic lettuce plants expressing CTB-Pins grew
normally and transgenes were maternally inherited in T1 progeny. This opens up the possibility for the
low-cost production and delivery of human therapeutic proteins, and a strategy for the treatment of
various other autoimmune diseases.
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Field production and functional evaluation of chloroplast-derived
interferon-α2b
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Type I interferons (IFNs) inhibit viral replication and cell growth and enhance the immune response,
and therefore have many clinical applications. IFN-α2b ranks third in world market use for a
biopharmaceutical, behind only insulin and erythropoietin. The average annual cost of IFN-α2b for
the treatment of hepatitis C infection is $26 000, and is therefore unavailable to the majority of patients
in developing countries. Therefore, we expressed IFN-α2b in tobacco chloroplasts, and transgenic
lines were grown in the field after obtaining United States Department of Agriculture Animal and
Plant Health Inspection Service (USDA-APHIS) approval. Stable, site-specific integration of
transgenes into chloroplast genomes and homoplasmy through several generations were confirmed.
IFN-α2b levels reached up to 20% of total soluble protein, or 3 mg per gram of leaf (fresh weight).
Transgenic IFN-α2b had similar in vitro biological activity to commercially produced PEG-Intron™
when tested for its ability to protect cells against cytopathic viral replication in the vesicular stomatitis
virus cytopathic effect (VSV CPE) assay and to inhibit early-stage human immunodeficiency virus
(HIV) infection. The antitumour and immunomodulating properties of IFN-α2b were also seen in
vivo . Chloroplast-derived IFN-α2b increased the expression of major histocompatibility complex
class I (MHC I) on splenocytes and the total number of natural killer (NK) cells. Finally, IFN-α2b
purified from chloroplast transgenic lines (cpIFN-α2b) protected mice from a highly metastatic
tumour line. This demonstration of high levels of expression of IFN-α2b, transgene containment and
biological activity akin to that of commercial preparations of IFN-α2b facilitated the first field
production of a plant-derived human blood protein, a critical step towards human clinical trials and
commercialization.

Keywords
antitumour; antiviral; gene containment; molecular ‘pharming’; plant-made cytokine

*Correspondence (fax 407-823-0956; e-mail daniell@mail.ucf.edu).
Author contributions and site of performance
PAA designed and contributed data for Figure 3a, Figure 4–Figure 6 and Table 2, interpreted the data and wrote the manuscript sections
related to these investigations. RF created chloroplast transgenic lines (as a graduate student) and contributed to the data in Figure 1. SC
contributed data to Figure 2 and Table 1 (as an undergraduate student). AC and AMC contributed the data in Figure 3b,c. KKO was
responsible for the data on the field growth of transgenic plants. HD conceived and designed this study, secured NIH and USDA funding,
interpreted the data, and wrote and revised several versions of the manuscript. All investigations reported here were performed at the
University of Central Florida, except the field growth of transgenic lines that was conducted by investigators at Chlorogen, Inc., St. Louis,
MO, USA.

Arlen et al.

Page 2

Introduction
NIH-PA Author Manuscript

The type I interferons (IFNs) are part of the body’s first line of defence against viral attack,
and also invasion by bacterial pathogens, parasites, tumour cells and allogeneic cells from
grafts (De Maeyer and De Maeyer-Guignard, 1988). IFN-α and IFN-β display significant
amino acid sequence homology (30%) and bind to the same receptor (Pestka et al., 1987).
Members of the IFN-α family were the first to be highly purified, sequenced, cloned and
produced by recombinant DNA (Henco et al., 1985). Although they are known for their
inhibition of viral replication (Vilcek and Sen, 1996), IFN-α is also involved in regulating
cytokine and cytokine receptor gene expression (Cousens et al., 1997), mediating cellular
proliferation and differentiation (Baron et al., 1992), modifying immune cell distribution
(Gresser et al., 1981; Ishikawa and Biron, 1993) and activating natural killer (NK) cell
cytotoxic activity (Trinchieri, 1989). Indeed, IFN-α is a potent inhibitor of cell growth (Pestka
et al., 1987). Perhaps most important, IFN-α may be a critical link between the innate and
adaptive immune responses (Brassard et al., 2002).
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Recombinant IFN-α2b was first approved by the Food and Drug Administration (FDA) in 1986
for the treatment of hairy cell leukaemia. Today, it is routinely administered for the treatment
of various cancers and viral diseases, but the cost of treatment is prohibitive in many developing
countries (Stuart-Harris, 1997). The average cost of treatment using the marketed recombinant
IFN-α2b is $26 000 for a 12-month course in the USA (Cowley, 2002).
The current therapeutic IFN-α2b is marketed under the names PEG-Intron™ and Intron®A
and is made in the microbial system Escherichia coli. Many eukaryotic proteins cannot be
expressed in prokaryotic hosts because the required formation of two disulphide bonds (Bodo
and Maurer-Fogy, 1986) presents a major limitation, adding to the cost of production of the
mature, biologically active IFN-α2b. As a result, IFN-α2b tends to aggregate to form inclusion
bodies that need to be solubilized, renatured and refolded into an active protein (Swaminathan
and Khanna, 1999). Other production platforms, such as silkworm using baculovirus (Maeda
et al., 1985) or phage vectors (Slocombe et al., 1982), have been used to express IFN-α2b at
low levels that are not competitive with the current system.
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The plant nuclear genome has been used to express human therapeutic proteins for more than
a decade (Horn et al., 2004). The expression of IFN-α2b and IFN-α8 has been achieved by
transforming potato nuclei (Ohya et al., 2001). In tobacco, only 0.000017% fresh weight of
transgenic leaves contained IFN-β (Edelbaum et al., 1992). In addition, negligible amounts of
IFN-α were produced in nuclear-transformed rice (Zhu et al., 2004). The low and variable
expression levels (caused by the position effect and gene silencing) using nuclear
transformation are less than adequate to be commercially feasible, in addition to the problems
of transgene containment that arise with field planting. Therefore, strategies are required to
increase expression levels in plants and to facilitate transgene containment, allowing rapid and
less expensive production of therapeutic proteins.
The chloroplast expression system is quite versatile in producing proteins as small as 20 amino
acids, e.g. magainin (DeGray et al., 2001), or as large as 135 kDa, e.g. Cry 1Ac (McBride et
al., 1995). Plastids can produce monomeric (Staub et al., 2000; Fernandez-San Millan et al.,
2003) or multimeric proteins, including cholera toxin B (CTB) (Daniell et al., 2001), CTB
fusion proteins (Limaye et al., 2006), and Guy’s 13 (Daniell et al., 2004a) and herpes simplex
virus (Mayfield et al., 2003) antibodies. Therapeutic proteins with 2–17 disulphide bonds,
including human serum albumin (Fernandez-San Millan et al., 2003) and somatotropin (Staub
et al., 2000), have already been produced in transgenic chloroplasts, with appropriate posttranslational modifications, including lipid modifications, e.g. OspA lipoprotein (Glenz et
al., 2006). The chloroplast expression system has also been used to produce fully functional
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vaccine antigens against bacterial pathogens, including cholera (Daniell et al., 2001), anthrax
(Watson et al., 2004; Koya et al., 2005) and tetanus (Tregoning et al., 2003), viral pathogens,
including canine parvovirus (Molina et al., 2004) and rotavirus VP6 (Birch-Machin et al.,
2004), and protozoan pathogens, including amoeba (Chebolu and Daniell, 2006). The correct
folding, disulphide bond formation and functionality of chloroplast-derived vaccine antigens
and therapeutic proteins have been demonstrated by several assays, including macrophage
lysis, GM1-ganglioside binding, systemic immune responses, protection against pathogen or
toxin challenge and growth or inhibition of cell cultures (Daniell et al., 2004a; Kamarajugadda
and Daniell, 2006). Multiple genes have been engineered via the chloroplast genome in a single
transformation event, facilitating the synthesis and assembly of multicomponent vaccines
(Quesada-Vargas et al., 2005). Therefore, any therapeutic protein, irrespective of size, can be
made with desired post-translational modifications, with the notable exception of glycosylation
(Daniell et al., 2004a; 2005a). However, a few foreign proteins have been highly unstable
within transgenic chloroplasts. For example, IFN-γ was degraded within chloroplasts (< 0.2%
TSP), but expression of up to 7% TSP was achieved via fusion with β-glucuronidase (GUS)
(Leelavathi and Reddy, 2003). Human insulin was similarly unstable in transgenic chloroplasts;
fusion with CTB resulted in high-level expression (up to 16% TSP) and facilitated oral delivery
studies to achieve protection against the development of insulitis in non-obese diabetic mice
(Ruhlman et al., 2007). Such N-terminal degradation is not unique to chloroplasts. All
commercially produced insulin in bacteria or yeast is produced as a fusion protein; when
expressed without fusion, insulin is rapidly degraded.
Plant chloroplasts are ideal bioreactors, and it has been shown that 1 acre of chloroplast
transgenic plants can produce up to 360 million doses of clean, safe and fully functional anthrax
vaccine antigen (Watson et al., 2004; Koya et al., 2005). This is a relatively rapid system for
scale-up, because a single tobacco plant (a non-food, non-feed crop) produces up to one million
seeds, which is adequate to plant more than 100 acres (8000 plants per acre and 40 metric tons
of leaf biomass per acre). Transgenes integrated into the chloroplast genome are maternally
inherited in most crops, ensuring that they are not spread via pollen, and thereby offering
transgene containment (Daniell et al., 1998; Daniell, 2002; Grevich and Daniell, 2005).
Alternatively, cytoplasmic male sterility can be engineered via the chloroplast genome, thereby
eliminating the production of viable pollen (Ruiz and Daniell, 2005). An additional advantage
is that transformed seeds can be stored indefinitely and vaccine antigens can be produced on
demand, eliminating the need to stockpile vaccine antigens under low temperature and with
limited shelf life.
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In this study, we investigate the expression of IFN-α2b in transgenic tobacco chloroplasts
(cpIFN-α2b), and evaluate the functionality of purified IFN-α2b using commercial IFNs as
comparative standards.

Results and discussion
The 5.9-kb universal chloroplast vector (Daniell et al., 2005b) used in this study contains
several unique features that facilitate the integration of cloned DNA into the plastid genome.
This process occurs exclusively through site-specific homologous recombination, thereby
excluding the foreign vector DNA and enhancing transgene expression. The pLD-CtV vector
incorporates the trnA and trnI genes (chloroplast transfer RNA transcripts coding for alanine
and isoleucine, respectively) from the inverted repeat region of the tobacco chloroplast genome
as flanking sequences for homologous recombination (Daniell et al., 2005b). This vector was
successfully used as the backbone for insertion of the expression cassette 5′UTR/HIS/THR/
IFNα2b (Figure 1a).
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Selection and regeneration of transgenic lines
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From seven bombarded Petit Havana leaves, 27 green shoots appeared after 4 weeks. From
eight bombarded LAMD-609 leaves, 12 green shoots appeared within 7 weeks, indicating that
the shoots from the low-nicotine tobacco LAMD-609 took longer to sprout and were less
numerous. Untransformed cells appeared bleached on the antibiotic because they did not
contain the aadA gene. For the second round of selection, the Petit Havana shoots were able
to thrive on 500 µg/mL spectinomycin, whereas the LAMD-609 transformants only grew when
the antibiotic concentration was decreased to 350 µg/mL spectinomycin.
Confirmation of homoplasmy
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For both tobacco varieties, Southern blots were performed to confirm integration of the
IFNα2b cassette using appropriate DNA probes. A 0.81-kb DNA fragment containing the
chloroplast trnI and trnA flanking sequences was used to probe total leaf DNA to determine
homoplasmy or heteroplasmy after bombardment with pLD-RF-IFNα2b (Figure 1a). This
determination was also used to estimate the chloroplast genome copy number. BamHI-digested
DNA from transformed plants produced a 9.9-kb fragment when probed (Figure 1b).
Untransformed plant DNA from both tobacco varieties produced a single 7.9-kb fragment,
indicating no integration of foreign DNA. All but one transgenic line exhibited only the 9.9kb fragment (Figure 1b), indicating homoplasmy; plant #3c showed both the 7.9- and 9.9-kb
fragments, indicating heteroplasmy. The attainment of homoplasmy in transformants provides
a potential integrated transgene copy number of 10 000 copies per tobacco leaf cell (100
chloroplasts per plant cell × 100 genomes per chloroplast), and indicates that homoplasmy can
be achieved in the T0 generation. Transgene integration and maintenance of homoplasmy were
demonstrated in subsequent generations (T1, T2, T3, etc.; data not shown).
Characterization of cpIFN-α2b
IFN-α2b is functional in its monomeric form, but has a tendency to aggregate (Wang, 1999).
For LAMD-609, monomers of cpIFN-α2b protein were detected at approximately 21.5 kDa
(Figure 1c), as a result of the presence of the polyhistidine tag and thrombin cleavage site, and
smaller than the PEG-Intron™ standard (approximately 32 kDa). For Petit Havana, monomers
of cpIFN-α2b protein were also detected at approximately 21.5 kDa (Figure 1d), slightly larger
than the size of the Intron®A standard (19.2 kDa). In addition, dimers and multimers of cpIFNα2b were observed in both LAMD-609 and Petit Havana.
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The physical condition of the plants, its age and external factors, such as illumination and
changes in temperature in the growth chamber and glasshouse, all contribute to the levels of
protein expressed. Using enzyme-linked immunosorbent assay (ELISA), we examined the
variation in cpIFN-α2b levels in young, mature and old leaves of the same transgenic plants
of Petit Havana and LAMD, as well as under different durations of illumination, employing
PEG-Intron™ and recombinant human IFN-α2b (rHu-IFN-α2b) as standards. In all transgenic
lines grown in the glasshouse, higher levels of cpIFN-α2b expression were obtained when rHuIFN-α2b was used as the standard (Figure 2). Old leaves showed the lowest levels of expression,
corresponding to senescence inducing high proteolytic activity. Both young and mature leaves
showed high levels of IFN-α2b expression, ranging from 1 to 3 mg/g fresh weight, or 8%–21%
TSP, in T1 LAMD transgenic lines (Figure 2a,b). In Petit Havana transgenic lines, IFN-α2b
expression ranged from 0.2 to 1.2 mg/g fresh weight, or 2%–14% TSP (Figure 2c,d). The
variation in expression levels may be the result of a decrease in cpIFN-α2b levels on continuous
illumination in Petit Havana transgenic lines; in LAMD transgenic lines, such illumination
increased IFN-α2b accumulation. This highlights the difference between Petit Havana and
LAMD in the toleration of continuous light. The differences in protein levels correlate with
differences in light intensity, as the same source of nutrition was provided to all transgenic
lines. It is also known that 5′ untranslated regions of the psbA gene, located upstream of the
Plant Biotechnol J. Author manuscript; available in PMC 2008 December 5.
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IFNα2b cassette, enhance the translation of the psbA gene in light (Eibl et al., 1999). The
dramatic difference in IFN-α2b levels in glasshouse-grown LAMD plants is most probably a
result of light-regulated translational enhancement by the psbA regulatory sequences.
Expression of cpIFN-α2b in field-grown biomass
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In addition to the glasshouse, plants grown in the field were also examined. Approximately
2.5 months after transplantation in October, the biomass on stalks was cut 15 cm above ground
with a forage harvester (Hege, Eging am See, Germany). From a single harvest, 107.7 kg of
biomass was collected, shipped and stored in a commercial freezer (−20 °C) prior to analysis
and purification. The plants had an average height of 43.2 cm and weighed 64 g. A single acre
of tobacco biomass can be harvested four to six times within a growing season. As a result,
there is the potential to generate greater than 1 metric ton of fresh biomass per acre under these
conditions. As expected, Petit Havana plants had less height and weight per plant, and therefore
less biomass per acre than commercial cultivars, which can generate up to 40 times more per
acre (Cramer et al., 1999). Based on 0.8 mg IFN-α2b per gram of leaf biomass, 107.7 kg of
harvested biomass contained about 87.2 g of IFN-α2b. The limited yield was the result of a
single harvest of biomass at a very early age because of premature flowering of Petit Havana
in the field. Lower expression of IFN-α2b was anticipated in young leaves because the psbA
regulatory sequence used to express IFN-α2b is developmentally regulated, and optimal levels
of expression are achieved only in mature leaves of fully grown plants (Fernandez-San Millan
et al., 2003; Daniell et al., 2004a; Watson et al., 2004; Koya et al., 2005; Limaye et al.,
2006).
We were able to generate 137.13 mg of IFN-α2b from 100 g of biomass at maturity in the
glasshouse (Table 1). On the basis of observed expression levels, this should yield 5.5 × 107
mg of IFN-α2b in 1 acre of tobacco plants. A weekly dose of PEG-Intron™ (Schering
Corporation, Kenilworth, NJ, USA), the E. coli-produced recombinant IFN-α2b treatment for
hepatitis C, is 70 µg for an average 70-kg male. Based on a purification efficiency of 50%,
approximately 400 million weekly doses for the treatment of hepatitis C can be produced in
just 1 acre.
Functional evaluation of cpIFN-α2b using vesicular stomatitis virus (VSV)
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cpIFN-α2b activity was first evaluated by its antiviral properties. The activity of IFN-α2b is
typically assayed by measuring its ability to inhibit the in vitro replication of VSV (Rubinstein
et al., 1981). Staining cells with crystal violet at the end of the assay enabled us to visualize
the degree of cytopathicity under the microscope. Representative photographs are shown in
Figure 3a. The mock controls (VSV alone and medium alone) were assigned protection values
of 0% (complete cytopathicity) and 100% (complete protection), respectively. To rule out any
toxic effects, IFN-α2b was tested in the absence of virus. As can be seen by the example of
PEG-Intron™, cells grew normally in the presence of up to tenfold higher concentrations of
IFN-α2b (Figure 3a). All experimental preparations of cpIFN-α2b protected cells, and did so
in a dose-dependent manner. Purified cpIFN-α2b protected cells even when diluted 500-fold
(data not shown). A crude extract of transgenic leaf material was still protective at the 1000fold dilution (Figure 3a). Crude extracts of non-transgenic tobacco leaves were not protective,
at any dilution, indicating that it is the presence of transgenic IFN-α2b in the plant that mediates
the protection.
Crystal violet staining also enabled us to quantify the biological activity of the various IFNα2b preparations tested. The activity is expressed in international units (IUs) and was calculated
by comparing the levels of protection with controls. cpIFN-α2b from both laboratory and field
sources was strongly protective (Table 2), as were the corresponding crude extracts. The
weekly dose of PEG-Intron™ is also depicted in the table, to illustrate the levels of activity
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achievable via the transgenic chloroplast system. As can be seen, 100 mg of transgenic leaf
material expressing IFN-α2b has approximately the same biological activity as one weekly
dose of PEG-Intron™.
Functional evaluation of cpIFN-α2b using human immunodeficiency virus (HIV)
To further investigate the antiviral properties of cpIFN-α2b, we assessed the protection of cells
from HIV-1 entry and integration. The targets for infection in this assay are TZM-BL cells, a
derivative of HeLa cells that express CD4, CCR5 and CXCR4, rendering them excellent targets
for infection by both tropic varieties of HIV. These cells also contain a luciferase expression
cassette that is driven by the HIV long terminal repeat (LTR). Thus, when HIV productively
infects TZM-BL, the high levels of Tat produced drive transcription by the endogenous LTR,
resulting in quantifiable luciferase expression.
Two different HIV isolates were tested: the CCR5-tropic strain BaL and the CXCR4-tropic
strain IIIB. PEG-Intron™ demonstrated approximately 80% inhibition of luciferase activity at
both dilutions tested (Figure 3b,c). cpIFN-α2b from laboratory-derived plants showed nearly
100% protection from infection by both HIV strains at the 10-fold dilution; at the 100-fold
dilution, protection from HIV BaL was nearly 60% (Figure 3b) and, from HIV IIIB, better than
80% (Figure 3c). cpIFN-α2b from field-derived plants also demonstrated strong protection:
better than 65% for both dilutions and both strains tested.

NIH-PA Author Manuscript

Protection by transgenic plant crude extract was also noted. For HIV BaL, better than 50%
protection was observed and, for HIV IIIB, better than 67% protection. Wild-type crude extract
did not protect cells at all from infection by HIV BaL, but did provide minimal protection (<
20%) from HIV IIIB, indicating that it is the IFN-α2b expressed by transgenic leaves that
provides the bulk of specific protection.
In summary, both forms of cpIFN-α2b tested (purified and crude extract, from both laboratory
and field sources) were protective in in vitro antiviral assays. The successful performance of
the transgenic plant crude extracts in the in vitro assays, with strong biological activity of
cpIFN-α2b, demonstrates the advantage of the higher levels of expression observed in
chloroplast transgenic lines. After performing initial in vitro studies using plant crude extracts,
all subsequent investigations were conducted with purified cpIFN-α2b; the results observed
were very similar to those of currently available commercial sources of IFN.
In vivo studies
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Amongst the myriad effects imparted by IFN-α2b, the up-regulation of major
histocompatibility complex class I (MHC I) molecules (de Waard-Siebinga et al., 1995) and
the activation of NK cells (Gidlund et al., 1978; Senik et al., 1979) comprise a major part of
its antiviral and antitumour properties. Our in vivo assays were designed to address whether
our preparations of cpIFN-α2b were similarly capable of regulating the immune response.
cpIFN-α2b up-regulates MHC I expression on splenocytes—Blind screens of more
than 100 sections of spleen tissue from each treatment condition were performed for the
expression of cell surface markers. Initially, the expression of MHC I on splenocytes was
analysed. Because all nucleated cells express MHC I antigens, we were interested in the relative
differences between the treatment groups. The basal level of MHC I expression of mouse spleen
tissue can be seen in the phosphate-buffered saline (PBS) treatment condition (Figure 4a).
Treatment with cpIFN-α2b increased MHC I expression to levels similar to those achieved by
PEG-Intron™ treatment. These results were confirmed by quantifying the
immunofluorescence emission data. Spleen tissue isolated from PBS-treated mice
demonstrated a mean fluorescence intensity (MFI) of MHC I expression of 74.7 units (Figure
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4b). Mice treated with PEG-Intron™ had a significantly higher MFI (88.02 units; P = 0.04).
Mice treated with cpIFN-α2b also had a significantly higher MFI (83.27 units; P = 0.003).
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cpIFN-α2b increases the number of NK cells in vivo—Spleen tissue was also screened
for the presence of NK cells. In PBS-treated mice, little staining of cells positive for the NK
cell markers CD49b and NK1.1 was found (Figure 4a). By contrast, more positive NK cell
staining was detected in mice treated with cpIFN-α2b. When the fluorescence emissions of the
overlaid images were quantified, spleen tissue isolated from mice treated with PBS
demonstrated a combined MFI (MFICD49b × MFINK1.1) of 3797 units (Figure 4c). Mice treated
with PEG-Intron™ showed a significantly higher combined MFI of 9366 units (P = 1.6 ×
10−9). Mice treated with cpIFN-α2b also showed a significantly higher combined MFI of 8284
units (P = 8.9 × 10−15).
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Finally, the splenocytes were analysed by flow cytometry. Representative plots are depicted
in Figure 5a. Splenocytes isolated from mice treated with either PEG-Intron™ or cpIFN-α2b
stained nearly 90% positive for MHC I expression (data not shown), and more than 6% were
positive for the expression of the NK cell marker CD49b (Figure 5c). Mice treated with PBS
showed significantly fewer splenocytes staining positive for CD49b (P = 0.04). By contrast,
mice treated with cpIFN-α2b showed nearly 5.5% of splenocytes staining positive for CD49b,
also a significant difference (P = 1.3 × 10−5). In addition, the MHC I-positive cell population
from mice treated with cpIFN-α2b preparations showed a nearly 20% greater MFI than that of
PBS-treated mice (Figure 5b), a significant difference (PEG-Intron™, P = 0.01; cpIFN-α2b,
P = 0.03).
Taken together, these data lend support to the concept that cpIFN-α2b possesses the biological
function of up-regulating MHC I expression and NK cell markers.
cpIFN-α2b inhibits tumour metastasis in vivo—IFN-α has well-characterized
antitumour activity in malignancies (Gutterman, 1994; Belardelli et al., 1998). The antitumour
properties of cpIFN-α2b were assessed against B16-F10 cells, an aggressive metastatic
melanoma cell line (Fidler et al., 1976).
The degree of tumour metastasis could be determined empirically by macroscopic observation
of the lungs after sacrifice (Figure 6a). Mice treated with PBS showed the highest degree of
metastasis, indicated by near-complete coverage of the lung with tumour. By contrast, mice
treated with either PEG-Intron™ or cpIFN-α2b exhibited quantifiably fewer black spots
(Figure 6a).
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These data were analysed further by calculating the colour intensity of the images, designed
to help quantify the relative intensity of tumour (black) on a background of healthy lung tissue
(red/pink). The calculations are summarized in Figure 6b, in which the mean colour intensity
(MCI) of each group is plotted. As expected, mice treated with the positive control preparation
(PEG-Intron™) had a mean MCI of 40.82 units, significantly higher than that of the animals
treated with PBS (21.58 units; P = 0.02). cpIFN-α2b also significantly reduced the tumour
metastasis to a mean MCI of 34.24 units (P = 1.1 × 10−7). These data suggest that the treatment
of mice with cpIFN-α2b mediates antitumour activity and helps protect mice from the
metastatic effects of the B16-F10 tumour line. Once again, as in previous assays, the
performance of cpIFN-α2b is comparable with that of its commercial counterpart.
In conclusion, we have expressed IFN-α2b in tobacco chloroplasts, and transgenic lines were
grown in the field after obtaining United States Department of Agriculture Animal and Plant
Health Inspection Service (USDA-APHIS) approval. Southern blots confirmed the stable, sitespecific integration of transgenes into chloroplast genomes and homoplasmy in several
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generations. Western blots detected monomeric and multimeric forms of cpIFN-α2b. ELISA
showed up to 20% of TSP, or 3 mg IFN per gram of leaf (fresh weight). cpIFN-α2b possesses
both in vitro and in vivo biological activity in both crude extract and purified forms. The induced
up-regulation of MHC I molecules and activation of NK cells are consistent with the critical
role played by IFN-α2b in early immune responses. MHC I is a necessary component of the
antiviral response, increasing the presentation of foreign peptides to circulating immune cells
primed for attack. NK cells survey the body for changes in MHC I expression, an indicator of
abnormal situations, such as cancer. The priming of NK cells mediated by IFN-α2b helps to
mobilize the immune system and facilitate the clearance of tumours. Our results provide a
simple and cost-effective method for the production of functional IFN-α2b.

NIH-PA Author Manuscript

The commercial potential of molecular ‘pharming’ of plant-made pharmaceuticals has resulted
in regulatory agencies formulating guidelines to protect the environment and consumers.
Clearly, the rationale and risks of molecular pharming are very different from those of the first
generation of crops genetically modified to enhance agronomic traits. In this study, we have
used chloroplast genetic engineering to minimize the transmission of transgenes via pollen.
We have also used a non-food/non-feed crop and expressed the therapeutic protein only in
vegetative tissues. In addition, the transgenic plants were harvested before any reproductive
structures appeared, thereby eliminating the spread of transgenes via pollen or seeds. This is
the first example of a human blood protein produced in the field in transgenic plants. Largescale production and purification in Good Manufacturing Practice (GMP) facilities should lead
to human clinical trials and further advances in this field.

Experimental procedures
Construction of the pLD-RF-IFNα2b vector
The IFNα2b gene was purchased from the American Type Culture Collection (Gwynne et
al., 1993) (ATCC #53371; Manassas, VA, USA) in E. coli strain JM83 K-12. Sequencing
results confirmed that the fragment in the pGL2BIFN vector was IFNα2b. Two overlapping
primers were used at the 5′ end of the IFNα2b gene to include a thrombin cleavage site and a
polyhistidine tag, with the reverse primer containing a NotI restriction site for further
subcloning. After confirmation of the DNA sequence, the gel-eluted polymerase chain reaction
(PCR) product was ligated into a Bluescript vector containing the 5′ untranslated region (UTR)
of the psbA gene. This fragment (5′UTR/HIS/THR/IFNα2b) was inserted into the universal
chloroplast vector pLD to create pLD-RF-IFNα2b. The recombinant DNA techniques were
carried out as detailed previously (Sambrook et al., 1989)
Bombardment and selection of transgenic shoots
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The Bio-Rad PDS-1000/He biolistic device (Bio-Rad, Hercules, CA, USA), a particle delivery
system, was used to bombard tobacco leaves (Kumar and Daniell, 2004; Daniell et al.,
2005b). Two varieties of tobacco (Nicotiana tabacum) were generated for the bombardment:
Petit Havana and LAMD-609 (low-nicotine hybrid produced by backcrossing a Maryland type
variety, MD-609, with a low-nicotine-producing burley variety, LA Burley 21) (Collins et
al., 1974). After recovering in the dark for 48 h, leaves were cut under the hood into 5-mm2
pieces and placed on regeneration medium of plants (RMOP) plates containing 500 µg/mL of
spectinomycin for the first round of selection for transformants (Daniell, 1997; Daniell et al.,
2005b). Approximately 4 weeks later, the shoots were cut into 2-mm2 pieces and transferred
to fresh RMOP plates containing spectinomycin for a second round of selection. During this
round of selection, the shoots that appeared were tested for cassette integration into the
chloroplast genome by PCR analysis. Finally, after 4 weeks of secondary selection, the shoots
were transferred to sterile jars containing fresh Murashige and Skoog medium without
hormones (MS0) medium with 500 µg/mL spectinomycin (Kumar and Daniell, 2004; Daniell
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et al., 2005b). When the shoots grew to fill the jars, the transgenic lines were transferred to
pots with soil containing no antibiotic. Potted plants were grown in a 16-h light/8-h dark
photoperiod in the growth chamber at 26 °C or in the glasshouse or field.
Southern blot analysis
Total plant DNA was extracted from transgenic T0 plants and untransformed tobacco plants
using the DNeasy Plant Mini Kit (Qiagen, Valencia, CA, USA). Total plant DNA was digested
with HincII and probed by the flanking sequence probe, which was obtained from the pUC-Ct
vector by digesting with BamHI and BglII to yield a 0.81-kb fragment (Figure 1a). The probe
was prepared by random primed 32P-labelling (Ready-To-Go DNA labelling beads; Amersham
Biosciences, Pittsburgh, PA, USA). The probes were hybridized to the membrane using the
Quick-hyb solution and protocol (Stratagene, La Jolla, CA, USA), as described previously
(Kumar and Daniell, 2004; Daniell et al., 2005b). The radiolabelled blots were exposed to Xray films and then developed in the X-ray film processor.
Immunoblot analysis
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Plant extraction buffer (PEB) was made fresh on the same day as the Western analysis, and
contained 100 mM NaCl, 10 mM ethylene-ediaminetetraacetic acid (EDTA) (pH 8), 200 mM TrisHCl (pH 8), 0.05% Tween-20, 0.1% sodium dodecylsulphate (SDS), 14 mM β-mercaptoethanol
(BME), 400 mM sucrose and 2 mM phenyl methyl sulphonyl fluoride (PMSF), which specifically
inhibits serine proteases, such as chymotrypsin, trypsin and thrombin. From each transgenic
Petit Havana and LAMD-609 line, leaf sections were cut and labelled as old (bottom), mature
(middle) and young (top) leaves. Leaf material (100 mg) was ground in liquid nitrogen in cold,
autoclaved mortars and pestles. PEB (200 µL) was added to each plant sample on ice and then
vortexed for 10 s. A mouse antihuman IFN-α antibody (Abcam, Cambridge, MA, USA) was
used for the immunoblot analysis of the extracted plant proteins.
ELISA
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Plant tissues were ground in liquid nitrogen using sterile mortar and pestles, and then placed
on ice. Plant protein extraction buffer (500 µL of 15 mM Na2CO3, 35 mM NaHCO3, 3 mM
NaN3, 0.1% Tween-20, pH 9.6) was added to each sample and vortexed briefly. The samples
were centrifuged at 4000 × g for 2 min and then placed back on ice. The supernatant was passed
through a 0.22-µm filter and transferred to a fresh tube. Dilutions of crude extract ranging from
1 : 5 to 1 : 5000 were made in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3,
pH 9.6). PEG-Intron™ (a covalent conjugate of recombinant IFN-α2b with monomethoxy
polyethylene glycol; Schering Corporation) was used as the standard and was also diluted in
coating buffer. Aliquots of 100 µL of the diluted plant protein extract and standards were
pipetted into a 96-well microtitre enzyme immunoassay (EIA) plate in duplicate. The plate was
covered with parafilm and incubated at room temperature for 4 h. The wells were washed three
times with 0.1% Tween-20 in phosphate-buffered saline (PBS-T), followed by three washes
with deionized water. The plate was patted dry on paper towels, without letting the wells go
completely dry. To detect the presence of IFN-α2b in each sample, 100 µL of mouse
monoclonal antibody against human IFN (clone MMHA-2, PBL Biomedical, Piscataway, NJ,
USA), diluted 1 : 2500 in PBS supplemented with 3% non-fat, powdered milk (Carnation) and
0.1% Tween-20 (P-T-M), was added to each well and incubated for 1 h at 37 °C. After
incubation, the wells were washed as above, and 100 µL of the secondary antibody (goat antimouse immunoglobulin G) conjugated to horseradish peroxidase (American Qualex, San
Clemente, CA, USA), diluted 1 : 5000 in P-T-M, was added to the wells and incubated for 1
h at 37 °C. After incubation, the wells were washed as above, and 100 µL of 3,3′,5,5′tetramethylbenzidine (TMB) substrate (American Qualex) was added to the wells. After
allowing 5 min for colour change, 100 µL of 2 M sulphuric acid was added to stop the reaction.
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The plate was immediately read on a microtitre plate reader (BioTek Instruments, Winooski,
VT, USA) using a 450-nm filter.
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Estimation of TSP
The TSP of plant crude extract was determined by the Bradford assay. Bovine serum albumin
(BSA; Sigma Chemical, St. Louis, MO, USA) was used as a standard in concentrations ranging
from 0.05 to 0.5 mg/mL. Aliquots of 10 µL of diluted plant extract and each standard were
added in duplicate to wells of a 96-well microtitre plate (Cellstar, Greiner, Nurtingen,
Germany). Bradford reagent (Bio-Rad Protein Assay, Bio-Rad) was diluted 1 : 4 with distilled
water, filtered, and 200 µL was added to each well and assayed as described previously (Kumar
and Daniell, 2004; Daniell et al., 2005b). The absorbance was read at 595 nm.
Field production of biomass expressing IFN-α2b
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IFN seeds in cultivar Nicotiana tabacum cv. ‘Petit Havana’ were initially propagated in the
glasshouse using standard tobacco production practices for clipping, fertilizer and pesticide
application suitable for field transplantation 30 days after seeding. The field was prepared prior
to transplantation by the application of 138 kg/acre of ammonium nitrate using a Drop
Spreader™ (Gandy Company, Owatonna, MN, USA), which was incorporated into the first
13 cm of soil using a Soil Finisher™ (John Deere, Moline, IL, USA). In August, seedlings
were transplanted using a mechanical transplanter on non-raised beds in 40-cm rows with 30cm plant spacings. The mean height of the transplanted seedlings was 15 cm, with an average
of five leaves each, and planted 10 cm deep. Approximately 0.26 acre containing 7369 plants
was seeded. At the time of transplantation, the field was prepared by applying insecticides [456
g/acre of Orthene (Monsanto, St. Louis, MO, USA) and 43 g/acre of Admire (Bayer
CropScience, Research Triangle Park, NC, USA)] and herbicides [231 g/acre of Spartan
(Chemical Products Technologies, Cartersville, GA, USA) and 922 g/acre of Command (FMC,
Philadelphia, PA, USA)]. Crop maintenance required application of the fungicides Quadris
(228 g/acre; Syngenta Crop Protection, Greensboro, NC, USA) and Acrobat MZ (48 g/acre;
BASF, Research Triangle Park, NC, USA) every 20–30 days to control blue mould infestation,
and a single application of Orthene (456 g/acre) to control aphid infestation.
In vitro assays to study the functionality of IFN
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Cells—Baby hamster kidney (BHK) and YAC-1 cells were obtained from ATCC. H9, PM1
and TZM-BL cells were obtained from the National Institutes of Health (NIH) AIDS Research
and Reference Reagent Program (Germantown, MD, USA). BHK and TZM-BL cells were
cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS). H9 cells were cultured in RPMI 1640
supplemented with 10% FBS and 100 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulphonic
acid (HEPES). PM1 cells were maintained at a density of (4–8) × 105 cells/mL in RPMI 1640
supplemented with 20% FBS and 100 mM HEPES. YAC-1 cells were cultured in RPMI 1640
supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/
L glucose and 1.5 g/L sodium bicarbonate.
IFN preparation—Crude extracts of transgenic and wild-type plants were generated using
PEB as described above. Histidine-tagged transgenic cpIFN-α2b was purified under native
conditions by passing crude extracts over HIS-Select spin columns (Sigma), according to the
manufacturer’s protocol. Flow-through, wash and eluate fractions were collected separately
for analysis. PEG-Intron™ was used as the positive control for IFN-α2b activity. We routinely
obtained greater than 85% purity of cpIFN-α2b (data not shown).
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VSV cytopathic effect (CPE) assay—The Indiana strain of VSV was propagated in BHK
cells (initial stocks were a kind gift from Dr Glen Barber, University of Miami, Miami, FL,
USA). The virus was titrated by plaque formation on BHK cells. All viral dilutions were made
in cell culture medium.
BHK cells were seeded in a 96-well plate 1 day prior to infection at a concentration of 1 ×
105 cells/mL. Cells were treated for 6 h prior to infection with either crude extract or purified
protein (25 µL), and then infected with 3000 plaque-forming units (PFUs) of VSV (25 µL);
control wells were treated with either VSV alone or medium alone. The assay was stopped 24
h later. The medium from each well was aspirated, and the cells were fixed and stained by the
addition of 100 µL of 0.5% (w/v in 70% methanol) crystal violet solution. After 1 min, the
crystal violet solution was decanted and the wells were gently rinsed with water. After drying,
the wells were examined under an inverted light microscope (Leica Microsystems, Wetzlar,
Germany) and photographs were taken with a digital camera (Olympus America, Melville,
NY, USA). The emission spectra of the crystal violet-stained wells were determined in a
microplate reader at 570 nm.
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Titrating IFN—The biological activity of the various preparations of IFN was calculated on
the basis of that of PEG-Intron™ standards and expressed in international units (IUs). The
mock controls (no IFN, no VSV) were assigned protection values of 0% and 100%,
respectively. A formula was generated that correlated the optical density (OD) readings at 570
nm with the percentage protection of the mocks. Then, using the calculated biological activity
of PEG-Intron™ (7 × 107 IU/mg), a second formula correlating the percentage protection with
the standardized IU of PEG-Intron™ was generated, and used to calculate the biological
activity of all experimental samples.
HIV-1 inhibition assay—The HIV-1 laboratory strains BaL (R5) and IIIB (X4) were
obtained from the National Institutes of Health AIDS Research and Reference Reagent
Program. HIV-1 BaL was propagated in PM1 cells over 16 days. Supernatants containing virus
were collected every other day, starting 5 days after infection, passed through a 0.45-µm pore
size filter and stored in aliquots at −80 °C. HIV-1 IIIB was similarly propagated using H9 cells.
Virus was quantified by ELISA for p24gag (Perkin-Elmer, Boston, MA, USA).
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The protocol for this assay has been described elsewhere (Venkataraman et al., 2005). TZMBL cells, also known as JC53-BL cells (Wei et al., 2002), which contain a luciferase expression
cassette driven by the HIV LTR, were seeded in 96-well dishes (4000 cells/well). After 24 h,
the cells were treated in triplicate with 50 µL of culture medium containing various preparations
of IFN-α2b or vehicle control (PBS). Culture medium or virus diluted in culture medium (2
ng/mL p24 for BaL and 5 ng/mL p24 for IIIB) in 50 µL was immediately added to each well
and allowed to incubate at 37 °C in 5% CO2 for 24 h. Luciferase activity was subsequently
measured with Bright-Glo reagents (Promega, Madison, WI, USA), according to the
manufacturer’s instructions, using an LMax luminometer (Molecular Devices, Sunnyvale, CA,
USA). The cytotoxicity and the metabolic activity of the cells were verified by a tetrazoliumbased (MTT) assay according to the manufacturer’s instructions (R&D Systems, Minneapolis,
MN, USA).
In vivo assays to study the functionality of IFN
Mice—Five-week-old C57BL/6 mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). Groups of mice were treated with PBS (three mice), PEG-Intron™
(five mice) or cpIFN-α2b (five mice) purified from transgenic tobacco leaves. Mice were
treated with 20 000 IU of cpIFN-α2b diluted in 100 µL of PBS. The biological activity was
based on the performance of purified protein in the VSV CPE assay. The doses were
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administered daily for three consecutive days via intraperitoneal injection using a tuberculin
syringe fitted with a 27-gauge needle. Mice were sacrificed 48 h after the final dose by carbon
dioxide inhalation.
Reagents—All antibodies used for flow cytometry and primary antibodies for
immunohistochemistry were obtained from BD Biosciences (San Jose, CA, USA); conjugated
antibodies for immunohistochemistry were obtained from Molecular Probes (Eugene, OR,
USA).
Collection of tissue samples—On sacrifice, mice were placed supine and the abdomen
was opened along the ventral midline. A 23-gauge butterfly needle was placed in the right
ventricle and sterile PBS was injected into the mouse for 5 min. One-half of the spleen was
excised and immediately placed in cold culture medium (RPMI 1640 supplemented with 10%
FBS). A solution of 4% paraformaldehyde (PFA) was then injected into the mouse via the right
ventricle for 15 min. The remaining portion of the spleen was then excised and placed
sequentially in 4% PFA, 10% sucrose, 20% sucrose and 30% sucrose, each for a period of 18–
24 h. Samples were placed in Tissue Freezing Medium (Triangle Biomedical Sciences,
Durham, NC, USA) and then flash frozen in 2-methylbutane (Sigma) over liquid nitrogen as
fixed tissue specimens.
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Immunohistochemistry—Sections of fixed frozen tissue (10 µm) were taken on a cryostat
slicer (Microm HM505E; Mikron Instruments, San Markos, CA, USA) at −20 °C. The sections
were mounted on Superfrost/Plus microscope slides (Fisher Scientific, Fair Lawn, NJ, USA).
The slides were washed three times with PBS, and then blocked with PBS containing 10%
BSA and 0.3% Triton X-100 for 1 h at room temperature. The sections were stained with one
of the following primary antibodies (all antibodies were diluted 1 : 250 in PBS containing 1%
BSA and 0.3% Triton X-100): mouse anti-H-2Kb (clone AF6-88.5), rat anti-CD49b (clone
DX5) or mouse anti-NK1.1 (clone PK136). The sections were incubated with primary antibody
overnight at 4 °C. The slides were washed three times and then incubated with either of the
following tagged secondary antibodies: rabbit anti-mouse/Alexa 488 or goat anti-rat Alexa
555. The sections were incubated with secondary antibody for 2 h at room temperature in the
dark. The slides were washed three times; if double staining was required, the sequence of
primary antibody staining, wash, secondary antibody staining and wash was repeated. At the
end of the staining procedure, the slides were fixed by adding 50 µL of VectaShield Mounting
Medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA,
USA). Coverslips were set and the slides were analysed on a Leica DM4000B fluorescent
microscope (Leica Microsystems). For each filter cube used, samples were acquired at the same
exposures to equilibrate light input. Then, using software-specific tools, the splenic tissue was
isolated and the MFI of antibody staining was tabulated to account for both positively and
negatively stained regions alike (Adobe Systems, San Jose, CA, USA).
Ex vivo preparation of splenocytes—Spleen tissue in culture medium was dissociated
using the plunger of a 10-mL syringe over a 70-µm cell strainer (BD Biosciences). The cells
were washed once with PBS containing 2% FBS and pelleted by centrifugation at 150 × g for
10 min. The supernatant was aspirated and the cells were resuspended in culture medium at a
concentration of 108 cells/mL.
Immunophenotyping—Splenocytes were analysed for cell surface expression of the
following markers: mouse anti-H-2Kb (clone AF6-88.5) conjugated to fluorescein
isothiocyanate (FITC), rat anti-CD49b (clone DX5) conjugated to phycoerythrin (PE) or mouse
anti-NK1.1 (clone PK136) conjugated to allophycocyanin (APC). Samples were analysed on
a FACSAria (BD Biosciences).
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Figure 1.

NIH-PA Author Manuscript

Confirmation of chloroplast integration and determination of homoplasmy/heteroplasmy in the
T0 generation of both varieties. (a) The 0.81-kb DNA probe containing chloroplast flanking
sequences. (b) DNA fragments of 7.9 kb indicate untransformed chloroplasts and DNA
fragments of 9.9 kb are observed when the chloroplast genome contains the integrated
transgenes. Lanes 1, 5, untransformed wild-type; lanes 2–4, transgenic LAMD-609 lines; lanes
6–9, transgenic Petit Havana lines. (c) Western blot of LAMD-609 transgenic plants expressing
chloroplast-derived interferon-α2b (cpIFN-α2b). Low-nicotine tissue extract separated by 15%
sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE), with cpIFN-α2b
detected by mouse monoclonal antibody against human IFN-α. Lane 1, 80 ng PEG-Intron™
standard; lane 2, protein marker; lane 3, wild-type (untransformed) LAMD-609; lanes 4–7,
transgenic LAMD-609 lines expressing monomers and multimers of cpIFN-α2b. (d) Western
blot of Petit Havana transgenic plants expressing cpIFN-α2b. Petit Havana leaf extract
separated by 15% SDS-PAGE, with cpIFN-α2b detected by mouse monoclonal antibody
against human IFN-α. Lane 1, 38 ng of Intron®A; lane 2, protein marker; lane 3, 190 ng of
Intron®A; lane 4, wild-type (untransformed) Petit Havana; lanes 5–7, transgenic Petit Havana
lines expressing monomers and multimers of cpIFN-α2b; lanes 8, 9, Escherichia colitransformed with IFN-α2b.
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Figure 2.
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Quantitation of interferon-α2b purified from chloroplast transgenic lines (cpIFN-α2b). Crude
extracts of transgenic leaf material were analysed for IFN-α2b expression by indirect enzymelinked immunosorbent assay (ELISA). Quantitation of transgenic IFN-α2b was performed on
the T1 generations of LAMD (a, b) and Petit Havana (c, d) plants. (a, c) Quantitation of cpIFNα2b as a percentage of total soluble protein (TSP). (c, d) Quantitation of cpIFN-α2b as
milligrams of transgenic protein per gram fresh leaf weight. Two different standards were used
in the ELISA: recombinant IFN-α2b with a covalent conjugate of monomethoxy polyethylene
glycol (PEG-Intron™) and recombinant human IFN-α2b (rHuIFN-α2b). Y, young leaves (top
few in the plant); M, mature leaves (fully developed); O, old leaves (bottom senescent leaves
with decreased pigments). Duration of illumination: 0, 1, 3 and 5 days of continuous
illumination. Error bars represent the standard error of the mean.
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Figure 3.
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Transgenic tobacco plants produce interferon-α2b (IFN-α2b) with biological activity in vitro.
(a) Transgenic IFN-α2b inhibits vesicular stomatitis virus (VSV)-induced cytopathicity. Baby
hamster kidney (BHK) cells were pretreated with the indicated samples for 24 h prior to VSV
exposure. At the conclusion of the assay, the cells were washed and stained with crystal violet
for microscopic examination. (b, c) Transgenic IFN-α2b inhibits human immunodeficiency
virus (HIV) infection, as determined by a decrease in luciferase expression. TZM-BL cells
were pretreated for 24 h with the indicated reagents, and then exposed to two different HIV
isolates: the CCR5-tropic strain BaL (b) and the CXCR4-tropic strain IIIB (c). All treatments
were performed in triplicate. Error bars represent the standard error of the mean. Asterisks
indicate P < 0.05.
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Figure 4.
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Immunohistochemical detection of the interferon response in mouse spleens. (a)
Representative photographs of mouse spleen tissue. The tissues were fixed and 10-µm sections
were stained for either the natural killer (NK) cell markers CD49b and NK1.1 or major
histocompatibility complex class I (MHC I). For NK cell marker staining, the channels were
read individually and also overlaid. It should be noted that, because of the natural expression
profile of MHC I, all cells are presumed to be positive. Therefore, these data are designed to
evaluate relative differences between the conditions. Isotype controls depict the background
fluorescence of the native tissue. Photographs were taken with a 20× objective and are
representative of more than 100 sections of each treatment condition. (b, c) Analysis of the
mean fluorescence intensity (MFI) of splenocytes stained for MHC I-positive cells (b) and NK
cells (c). All tissue samples were acquired with equivalent MFI. Error bars in (b) and (c)
represent the standard error of the mean. Asterisks indicate statistical comparisons between
PEG-Intron™ and phosphate-buffered saline (PBS), and interferon-α2b purified from
chloroplast transgenic lines (cpIFN-α2b) and PBS, with significant P values of less than 0.05.
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Figure 5.

Phenotypic analysis of splenocytes. Total splenocytes isolated from the various groups of mice
in this study were analysed by flow cytometry for surface marker expression. (a) Representative
flow cytometry plots showing splenocyte expression of major histocompatibility complex class
I (MHC I) and CD49b. Quadrant positions are based on isotype controls. (b) Comparison of
the mean fluorescence intensity (MFI) of MHC I across the various treatment groups. All cells
comprising the MHC I-positive population (i.e. both CD49b-positive and CD49b-negative
populations) are represented. (c) Comparison of the expression of natural killer (NK) cell
markers (CD49b and NK1.1) across the various treatment groups. The data in (b) and (c)
represent the means of each treatment group. Error bars represent the standard error of the
mean. Asterisks indicate statistical comparisons between PEG-Intron™ and phosphatebuffered saline (PBS), and interferon-α2b purified from chloroplast transgenic lines (cpIFNα2b) and PBS, with significant P values of less than 0.05.
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Figure 6.
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Transgenic tobacco plants produce interferon-α2b (IFN-α2b) with biological activity in vivo.
(a) Photographs of lungs of mice injected with the metastatic tumour B16-F10. Mice were
treated via intraperitoneal injection, as indicated, for three consecutive days. (b) Mean colour
intensity of tumour metastases. Photographs of lung samples were analysed for colour intensity.
All samples were photographed with equal exposure settings. A calculation of total colour was
then achieved by selecting only those pixels that corresponded to the lung tissue. The mean
colour intensity was calculated for all samples of a particular group. The lower the intensity,
the greater amount of black (tumour) in the image. Error bars represent the standard error of
the mean. Asterisks indicate statistical comparisons between PEG-Intron™ and phosphatebuffered saline (PBS), and purified cpIFN-α2b and PBS, with significant P values of less than
0.05.
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3.20
7.80
4.50

Leaves per plant

3.50
16.00
0.25

IFN-α2b per leaf (mg)

2.50
8.00
5.00

Average weight per
leaf (g)

1.40
2.00
0.05

IFN-α2b in fresh leaf
(mg/g)

11.20
124.80
1.13
137.13

IFN-α2b per age group (mg)
(no. leaves × [IFN-α2b] per
leaf)

Young leaves, top 2–3 leaves; old leaves, bottom 2–3 senescent leaves; mature leaves, selected from the middle of the plant. cpIFN-α2b levels were quantified by enzyme-linked immunosorbent assay
(ELISA).

Young
Mature
Old
Total amount of recombinant IFN-α2b per plant

Leaf age
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Yield of interferon-α2b purified from chloroplast transgenic lines (cpIFN-α2b) in LAMD transgenic lines grown in the glasshouse
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Table 2

Biological activity of interferon-α2b (IFN-α2b) preparations
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Sample

Concentration (IU/mL)*

Purified cpIFN-α2b (laboratory sample)
Purified cpIFN-α2b (field sample)
cpIFN-α2b crude extract (laboratory sample)
cpIFN-α2b crude extract (field sample)
Wild-type crude extract
PEG-Intron™ (maximum weekly dose)†

7.7 × 107
1.3 × 108
1.3 × 106
2.8 × 106
4.5 × 100
1.1 × 106

Baby hamster kidney (BHK) cells were pretreated with the indicated samples for 24 h prior to vesicular stomatitis virus (VSV) exposure. Concentrations
were determined by comparing the results of each experimental condition with the performance of PEG-Intron™, the positive control. These data represent
the mean of four independent experiments, with each treatment performed in duplicate.
*

IU: International units, calculated by comparison with a leucocyte reference standard obtained from the National Institute of Allergy and Infectious
Diseases (NAID) Repository.

†
The maximum weekly dose is based on the manufacturer’s specified dosage and is calculated for a 70-kg individual.
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